Washington Ordered to Cover Hepatitis C Drugs During LawsuitBy
Hepatitis C drugs cost as much as $94,500 before discounts
Washington verdict may set precedent for treatments nationally
Washington’s Medicaid program must pay for expensive hepatitis C treatments like Gilead Sciences Inc.’s Harvoni ahead of a trial to determine whether the state can exclude the medicine from being covered.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.